Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUPPRESS: Sequential Natalizumab-Alemtuzumab in RRMS
NCT03135249Phase 4Completed
- Sponsor
- UT Southwestern Medical Center
- Start
- May 2018
- Primary completion
- Nov 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of alemtuzumab in relapsing-remitting multiple sclerosis (RRMS), sponsored by UT Southwestern Medical Center. Started May 2018; status: completed.
02
Drugs
alemtuzumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT03135249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03135249.